Home » Stocks » Monopar Therapeutics

Monopar Therapeutics, Inc. (MNPR)

Stock Price: $7.18 USD 0.07 (0.98%)
Updated Jul 2, 2020 4:00 PM EDT - Market closed

Stock Price Chart

Key Info

Market Cap 76.35M
Revenue (ttm) n/a
Net Income (ttm) -3.94M
Shares Out 10.63M
EPS (ttm) -0.42
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 2, 2020
Last Price $7.18
Previous Close $7.11
Change ($) 0.07
Change (%) 0.98%
Day's Open 7.47
Day's Range 7.12 - 7.69
Day's Volume 4,015
52-Week Range 4.94 - 48.00

More Stats

Market Cap 76.35M
Enterprise Value 63.76M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 10.63M
Float 2.24M
EPS (basic) -0.41
EPS (diluted) -0.42
FCF / Share -0.30
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 3,681
Short Ratio 0.45
Short % of Float 0.15%
Beta n/a
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 6.97
Revenue n/a
Operating Income -4.05M
Net Income -3.94M
Free Cash Flow -3.15M
Net Cash 12.59M
Net Cash / Share 1.18
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -26.39%
ROE -43.37%
ROIC 2,403.60%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (2)

Buy 2
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: Buy

Price Target

$41.00*
(471.03% upside)
Low
40.0
Current: 7.18
High
42.0
Target: 41.00
*Average 12-month price target from 2 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year2019201820172016
Revenue----
Operating Income-4.32-3.33-16.60-1.19
Net Income-4.22-3.23-16.55-1.19
Shares Outstanding9.329.298.789.29
Earnings Per Share-0.45-0.35-1.89-
Operating Cash Flow-3.02-2.68-2.63-1.19
Free Cash Flow-3.02-2.68-2.63-1.19
Cash & Equivalents13.216.899.782.87
Net Cash / Debt13.216.899.782.87
Assets13.357.329.932.90
Liabilities0.720.400.310.06
Book Value12.636.929.622.83
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Monopar Therapeutics, Inc.
Country United States
Employees 6
CEO Chandler Drew Robinson

Stock Information

Ticker Symbol MNPR
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: MNPR

Description

Monopar Therapeutics Inc., a biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the United States. It is involved in developing Validive, a clonidine mucobuccal tablet that is in Phase III for the treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; Camsirubicin, a topoisomerase II-alpha targeted analog of doxorubicin engineered to retain anticancer activity and for minimizing toxic effects on the heart; and MNPR-101, a humanized monoclonal antibody for treating advanced solid cancers. The company has a collaboration Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; and NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19. Monopar Therapeutics Inc. was founded in 2014 and is headquartered in Wilmette, Illinois.